ATE265433T1 - Verbesserte matrix-metallprotease-inhibitoren - Google Patents
Verbesserte matrix-metallprotease-inhibitorenInfo
- Publication number
- ATE265433T1 ATE265433T1 AT92901322T AT92901322T ATE265433T1 AT E265433 T1 ATE265433 T1 AT E265433T1 AT 92901322 T AT92901322 T AT 92901322T AT 92901322 T AT92901322 T AT 92901322T AT E265433 T1 ATE265433 T1 AT E265433T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- protease inhibitors
- matrix metal
- image
- aryl
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title abstract 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000002184 metal Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- -1 cyclic amine Chemical class 0.000 abstract 2
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/615,798 US5183900A (en) | 1990-11-21 | 1990-11-21 | Matrix metalloprotease inhibitors |
| US07/747,752 US5189178A (en) | 1990-11-21 | 1991-08-20 | Matrix metalloprotease inhibitors |
| PCT/US1991/008723 WO1992009556A1 (en) | 1990-11-21 | 1991-11-21 | Improved matrix metalloprotease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE265433T1 true ATE265433T1 (de) | 2004-05-15 |
Family
ID=27087601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92901322T ATE265433T1 (de) | 1990-11-21 | 1991-11-21 | Verbesserte matrix-metallprotease-inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5189178A (de) |
| EP (1) | EP0558648B1 (de) |
| JP (1) | JP2736285B2 (de) |
| AT (1) | ATE265433T1 (de) |
| AU (1) | AU662504B2 (de) |
| CA (1) | CA2096221A1 (de) |
| DE (1) | DE69133385T2 (de) |
| WO (1) | WO1992009556A1 (de) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5239078A (en) * | 1990-11-21 | 1993-08-24 | Glycomed Incorporated | Matrix metalloprotease inhibitors |
| US5892112A (en) * | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| US5268384A (en) * | 1990-11-21 | 1993-12-07 | Galardy Richard E | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
| WO1992022523A2 (en) * | 1991-06-14 | 1992-12-23 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
| EP0642353A1 (de) * | 1992-05-14 | 1995-03-15 | Oncologix, Inc. | Behandlung des vaskularen permeabilitätssyndroms und der kollagenase induzierten krankheit durch administrieren von inhibitoren der matrix-metalloproteinase(20.01.94) |
| AU666727B2 (en) * | 1992-06-25 | 1996-02-22 | F. Hoffmann-La Roche Ag | Hydroxamic acid derivatives |
| GB9213473D0 (en) * | 1992-06-25 | 1992-08-12 | Hoffmann La Roche | Hydroxamic acid derivatives |
| CA2160139A1 (en) * | 1993-04-07 | 1994-10-13 | Richard Edward Galardy | Synthetic matrix metalloprotease inhibitors and uses thereof |
| US6013792A (en) * | 1993-08-05 | 2000-01-11 | Syntex (U.S.A.), Inc. | Matrix metalloprotease inhibitors |
| US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
| UA48121C2 (uk) * | 1993-11-04 | 2002-08-15 | Сінтекс (С.Ш.А.) Інк. | Інгібітори матричних металопротеаз і фармацетична композиція на їх основі |
| US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
| US5476939A (en) * | 1993-12-30 | 1995-12-19 | Abbott Laboratories | Certain pyridyl and isoquinolyl carbinolamine derivatives |
| GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
| GB9411088D0 (en) * | 1994-06-03 | 1994-07-27 | Hoffmann La Roche | Hydroxylamine derivatives |
| GB9411598D0 (en) * | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
| GB9416897D0 (en) * | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
| JPH08114884A (ja) * | 1994-08-25 | 1996-05-07 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| JP3505274B2 (ja) * | 1994-08-25 | 2004-03-08 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
| US5639746A (en) * | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
| EA003294B1 (ru) * | 1995-12-08 | 2003-04-24 | Агурон Фармасьютикалс, Инк. | Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения |
| US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
| US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| DK0780386T3 (da) * | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
| US5851800A (en) * | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| TR199900429T2 (xx) * | 1996-08-28 | 1999-05-21 | The Procter & Gamble Company | Spirosiklik metaloproteaz inhibit�rleri. |
| ATE226573T1 (de) * | 1996-08-28 | 2002-11-15 | Procter & Gamble | Heterozyklische metalloproteaseinhibitoren |
| HUP0000505A3 (en) * | 1996-08-28 | 2001-12-28 | Procter & Gamble | Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them |
| CN1228771A (zh) * | 1996-08-28 | 1999-09-15 | 普罗克特和甘保尔公司 | 1,3－二杂环金属蛋白酶抑制剂 |
| HUP9903916A3 (en) * | 1996-08-28 | 2001-06-28 | Procter And Gamble Co Cincinna | Phosphinic acid amides and pharmaceutical compositions containing the same |
| US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| JP2002515898A (ja) * | 1997-02-25 | 2002-05-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ヒトの皮膚での経時老化を防止および治療するための方法および組成物 |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| CN1265647A (zh) | 1997-07-31 | 2000-09-06 | 普罗克特和甘保尔公司 | 无环金属蛋白酶抑制剂 |
| US6329400B1 (en) | 1998-08-26 | 2001-12-11 | Glaxo Wellcome Inc. | Formamide compounds as therapeutic agents |
| GB9818605D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therepeutic agents |
| US6172064B1 (en) | 1998-08-26 | 2001-01-09 | Glaxo Wellcome Inc. | Formamides as therapeutic agents |
| US6794518B1 (en) * | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| KR20010102486A (ko) | 1999-03-03 | 2001-11-15 | 데이비드 엠 모이어 | 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제 |
| WO2003094954A1 (en) * | 2001-09-25 | 2003-11-20 | Quick Med Technologies, Inc. | Composition and method for minimizing or avoiding adverse effects of vesicants |
| AU2003233154A1 (en) | 2002-06-10 | 2003-12-22 | Pfizer Inc. | Metabolites of prinomastat and their sythesis |
| AU2003257089A1 (en) * | 2002-07-31 | 2004-02-16 | University Of Florida | Antimicrobial and antiproteolytic wound dressing |
| US20080139512A1 (en) * | 2002-09-25 | 2008-06-12 | Quick-Med Technologies, Inc. | Method for minimizing or avoiding adverse effects of vesicants |
| AU2003300379A1 (en) * | 2002-12-27 | 2004-07-29 | Angiotech Pharmaceuticals, Inc. | Compositions and methods of using collagen and MMPI |
| WO2004060346A2 (en) | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| ATE517926T1 (de) | 2003-04-04 | 2011-08-15 | Yeda Res & Dev | Antikörper zur hemmung der aktivität von mmp-2 und mmp-9 |
| AU2004263900A1 (en) | 2003-08-08 | 2005-02-17 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
| IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
| US7914771B2 (en) | 2004-03-09 | 2011-03-29 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
| WO2006009325A1 (ja) * | 2004-07-23 | 2006-01-26 | Ono Pharmaceutical Co., Ltd. | メタロプロテアーゼ阻害剤 |
| GB0421308D0 (en) * | 2004-09-24 | 2004-10-27 | Amersham Plc | Enzyme inhibitor imaging agents |
| AU2008277257B2 (en) | 2007-07-15 | 2014-03-06 | Hillman, Yitzchak Mr | Disease treatment via antimicrobial peptides or their inhibitors |
| BRPI0814479A2 (pt) | 2007-08-15 | 2016-07-12 | Yeda Res & Dev | "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica" |
| GB0722484D0 (en) * | 2007-11-15 | 2007-12-27 | Ucl Business Plc | Solid compositions |
| US20090209447A1 (en) | 2008-02-15 | 2009-08-20 | Michelle Meek | Cleaning compositions |
| WO2009156994A1 (en) * | 2008-06-24 | 2009-12-30 | Hadasit Medical Research Services And Development Ltd. | Ccl20-specific antibodies for cancer therapy |
| ES2349972B1 (es) | 2009-02-16 | 2011-11-24 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas. |
| JP2012532246A (ja) | 2009-07-09 | 2012-12-13 | ザ プロクター アンド ギャンブル カンパニー | 比較的低濃度の水溶性電解質を含む触媒性洗濯洗剤組成物 |
| MX2012000480A (es) | 2009-07-09 | 2012-01-27 | Procter & Gamble | Composiciones detergente catalitica de lavanderia que comprende niveles relativamente bajos de electrolitos solubles en agua. |
| CN102822202B (zh) | 2010-01-27 | 2015-07-22 | 耶达研究及发展有限公司 | 抑制金属蛋白的抗体 |
| CN103037891A (zh) | 2010-06-03 | 2013-04-10 | 雷蒙特亚特特拉维夫大学有限公司 | 治疗糖尿病的方法和能够治疗糖尿病的组合物 |
| US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
| CN103370337B (zh) | 2010-10-28 | 2015-12-09 | 耶达研究及发展有限公司 | 用于产生针对金属酶的抗体的方法 |
| US9061006B2 (en) | 2011-03-08 | 2015-06-23 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (PKU) |
| MX2014015205A (es) | 2012-06-14 | 2015-08-14 | Ambrx Inc | Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear. |
| WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| CA2977607A1 (en) | 2015-02-26 | 2016-09-01 | Jacob Schneiderman | Methods and compositions relating to leptin antagonists |
| EP3294280A1 (de) | 2015-05-11 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Citrinhemmer zur behandlung von krebs |
| WO2017042816A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Ablation of perforin positive dendritic cells in cancer treatment |
| EP3176183A1 (de) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Zusammensetzungen und verfahren zur behandlung von krebs ohne resistenz gegen einen tyrosinkinasehemmer (tki) |
| WO2017122203A1 (en) | 2016-01-11 | 2017-07-20 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
| US11262358B2 (en) | 2016-04-06 | 2022-03-01 | Technion Research & Development Foundation Limited | Infiltrating immune cell proportions predict anti-TNF response in colon biopsies |
| IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
| WO2020079692A1 (en) | 2018-10-17 | 2020-04-23 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof |
| US12509512B2 (en) | 2019-06-27 | 2025-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3A antibodies and uses thereof |
| WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
| WO2021076712A1 (en) * | 2019-10-15 | 2021-04-22 | Ophirex, Inc. | Early management and prevention of sepsis and sepsis-like syndromes |
| IL293729A (en) | 2019-12-11 | 2022-08-01 | Ichilov Tech Ltd | A non-invasive test to identify and monitor systemic inflammation |
| IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
| IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
| EP4359439A1 (de) | 2021-06-24 | 2024-05-01 | Yeda Research and Development Co. Ltd | Kombinationstherapie zur behandlung von krebs mit einem anti-egfr-antikörper und einem axl-inhibitor |
| IT202100023357A1 (it) | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptidi con attività anti-angiogenica |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| EP4584297A1 (de) | 2022-09-11 | 2025-07-16 | Yeda Research and Development Co. Ltd | Anti-klk4-antikörper und verwendungen davon |
| GB202316777D0 (en) | 2023-11-01 | 2023-12-13 | Cambridge Entpr Ltd | New therapeutic use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291048A (en) * | 1978-07-06 | 1981-09-22 | Joseph Gold | Method of treating tumors and cancerous cachexia with L-tryptophan |
| JPS5758626A (en) * | 1980-09-26 | 1982-04-08 | Rikagaku Kenkyusho | Carcinostatic agent |
| GB8311286D0 (en) * | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| US4558034A (en) * | 1984-01-31 | 1985-12-10 | The Board Of Trustees Of The University Of Kentucky | Inhibitors of bacterial collagenase |
| DE3482590D1 (de) * | 1984-04-12 | 1990-08-02 | Searle & Co | Carboxyalkyl-peptid-derivate. |
| US4698342A (en) * | 1985-07-16 | 1987-10-06 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
| US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| US4681894A (en) * | 1986-09-26 | 1987-07-21 | Ortho Pharmaceutical Corporation | Hydroxamic acids and esters |
| ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
| FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
| DE3889726T2 (de) * | 1987-03-17 | 1994-10-13 | Res Corp Technologies Inc | Synthetische inhibitoren von säugetier-collagenase. |
| CA1337400C (en) | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
| US4943587A (en) * | 1988-05-19 | 1990-07-24 | Warner-Lambert Company | Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition |
| US5114953A (en) * | 1990-11-21 | 1992-05-19 | University Of Florida | Treatment for tissue ulceration |
| US5239078A (en) * | 1990-11-21 | 1993-08-24 | Glycomed Incorporated | Matrix metalloprotease inhibitors |
| JPH05503719A (ja) * | 1990-12-03 | 1993-06-17 | セルテック リミテッド | ペプチジル誘導体 |
-
1991
- 1991-08-20 US US07/747,752 patent/US5189178A/en not_active Expired - Lifetime
- 1991-11-21 AT AT92901322T patent/ATE265433T1/de not_active IP Right Cessation
- 1991-11-21 AU AU90958/91A patent/AU662504B2/en not_active Ceased
- 1991-11-21 DE DE69133385T patent/DE69133385T2/de not_active Expired - Lifetime
- 1991-11-21 EP EP92901322A patent/EP0558648B1/de not_active Expired - Lifetime
- 1991-11-21 JP JP4501548A patent/JP2736285B2/ja not_active Expired - Lifetime
- 1991-11-21 WO PCT/US1991/008723 patent/WO1992009556A1/en not_active Ceased
- 1991-11-21 CA CA002096221A patent/CA2096221A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2096221A1 (en) | 1992-05-22 |
| EP0558648B1 (de) | 2004-04-28 |
| EP0558648A4 (en) | 1993-11-24 |
| WO1992009556A1 (en) | 1992-06-11 |
| JP2736285B2 (ja) | 1998-04-02 |
| AU662504B2 (en) | 1995-09-07 |
| AU9095891A (en) | 1992-06-25 |
| JPH05508163A (ja) | 1993-11-18 |
| DE69133385D1 (de) | 2004-06-03 |
| EP0558648A1 (de) | 1993-09-08 |
| DE69133385T2 (de) | 2005-02-24 |
| US5189178A (en) | 1993-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69133385D1 (de) | Verbesserte matrix-metallprotease-inhibitoren | |
| ATE157963T1 (de) | Verbesserte matrix metallprotease inhibitoren | |
| DE69129236D1 (de) | Behandlung für gewebeulzerationen | |
| NO914356D0 (no) | Mono n-substituerte 1,4,7,10-tetraazacyklododecan-derivater | |
| EP0513379A4 (en) | 2-arylthiazole derivative and pharmaceutical composition containing the same | |
| DE69232907D1 (de) | Neue heterocyclische/cyclische amine | |
| FR2725986B1 (fr) | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| ATE299861T1 (de) | Ppar-(gamma) agonisten zur behandlung von type ii diabetes | |
| DK300680A (da) | 5-amino-2,4,6-trijodisophtal-syre-bisamider og fremgangsmaade til fremstilling heraf samt anvendelse heraf i roentgenkontrastmidler | |
| DK0887350T3 (da) | Nye chromenderivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende disse | |
| ATE137757T1 (de) | Gem-diphosphonsäuren, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel | |
| ES2057216T3 (es) | N-(1,4-benzodiazepin-3-il) amidas de acidos 1h-indol-2-carboxilicos condensados en posiciones 1,7. | |
| PE20001241A1 (es) | Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores | |
| ATE213496T1 (de) | Heterozyclische verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| ATE223915T1 (de) | Neue heterozyklische chemie | |
| PL323339A1 (en) | Novel benzopyranic compounds, method of obtaining them and pharmaceutic compositions containing such compounds | |
| DK0588797T3 (da) | N- 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracen-yl carbonyl aminosyrer nyttige ved behandling af osteoartikulære lidelser | |
| FR2609603B1 (fr) | Agents edulcorants derives des acides guanidinoacetique et ethanamidinoacetique, procede pour edulcorer des produits divers, et compositions contenant de tels agents edulcorants | |
| NO931844L (no) | Forbedrede matriks metallproteasehemmere | |
| EP0571593A4 (de) | Nichtionische jodhaltige Röntgenstrahlenkontrastmittel, Verfahren zu ihrer Herstellung und diese enthaltenden Zusammensetzungen. | |
| NO931841L (no) | Forbedrede matriksmetallproteasehemmere | |
| ID21677A (id) | Proses pembuatan n-[2-(dimetilamino)etil]-akridin-4-karboksamida | |
| ATE221530T1 (de) | Verfahren zur n-alkylierung von cyclischen cyanamidinen | |
| NO931803L (no) | Behandling av vevsulkerasjon | |
| DE68910090D1 (de) | Verwendung heterozyklischer Amide zur Verhinderung der Tumormetastasierung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |